Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing targeted therapies using its proprietary Diffusphere™ technology. This technology enables extended-release drug delivery directly to diseased tissues, aiming to improve treatment outcomes while minimizing side effects. Eupraxia's clinical pipeline includes therapies for eosinophilic esophagitis and other inflammatory diseases, addressing high-need areas where existing treatments are inadequate. The company operates primarily in North America, targeting healthcare providers and patients in need of more effective therapeutic options.
- Website
- eupraxiapharma.com
- Issuer profile
- All listings